KR20170014332A - Composition for preventing and treatment of osteoporosis - Google Patents
Composition for preventing and treatment of osteoporosis Download PDFInfo
- Publication number
- KR20170014332A KR20170014332A KR1020150107475A KR20150107475A KR20170014332A KR 20170014332 A KR20170014332 A KR 20170014332A KR 1020150107475 A KR1020150107475 A KR 1020150107475A KR 20150107475 A KR20150107475 A KR 20150107475A KR 20170014332 A KR20170014332 A KR 20170014332A
- Authority
- KR
- South Korea
- Prior art keywords
- citron
- alcohol
- extract
- powder
- osteoporosis
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims description 40
- 240000004307 Citrus medica Species 0.000 claims abstract description 86
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 63
- 239000000284 extract Substances 0.000 claims abstract description 53
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 230000036541 health Effects 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 235000013376 functional food Nutrition 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 12
- 241000207199 Citrus Species 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 35
- 238000000605 extraction Methods 0.000 claims description 21
- 230000004072 osteoblast differentiation Effects 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 235000004347 Perilla Nutrition 0.000 claims 1
- 244000124853 Perilla frutescens Species 0.000 claims 1
- 241000195493 Cryptophyta Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 24
- 210000000988 bone and bone Anatomy 0.000 description 20
- 241000700159 Rattus Species 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000012675 alcoholic extract Substances 0.000 description 6
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940041476 lactose 100 mg Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000248349 Citrus limon Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000002876 effect on osteoporosis Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 235000019985 fermented beverage Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 229940106582 estrogenic substances Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Abstract
The present invention relates to a pharmaceutical composition and a health functional food for preventing or treating osteoporosis containing an alcohol extract of citron as an active ingredient. The present invention also relates to a method for extracting citrus algae which is optimized for preventing and treating osteoporosis without destroying the active ingredients of osteoporosis prevention and treatment efficacy as much as possible.
Description
The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis.
Osteoporosis is a disease caused by collapse of the balance between osteoblast and osteoclast, and bone resorption is higher than osteogenesis. In the onset of osteoporosis, the lime of the bone tissue is reduced, and the density of the bone becomes thinner, thereby widening the bone marrow. As the condition progresses, the bones become weaker, so that even a small impact is liable to fracture. It is known that osteoporosis is caused by aging, lack of exercise, low body weight, smoking, low calcium diet, menopause, and ovarian resection.
Most osteoporosis medicines currently on the market are estrogenic substances, which cause side effects such as cancer, gallstones and thrombosis when administered over a long period of time. Osteoporosis is a disease that can not be treated only by short-term administration of a drug, and long-term administration of the drug is indispensable. Therefore, it is necessary to develop a new drug having a drug efficacy sufficient to replace estrogen without the side effects mentioned above even when the drug is administered for a long time.
Most conventional osteoporosis medicines focus on the regulation of the imbalance between osteoclasts and osteoblasts. However, it is known that osteoporosis is greatly affected by bone marrow-derived adipocytes as well as bone-related cells, and prevention and treatment of osteoporosis by inhibiting adipocyte formation or developing drugs capable of converting existing adipocytes into osteoblasts It is attracting attention as a new goal. This is based on the fact that osteoblasts and adipocytes have the same precursors and that the differentiation of osteoblast cells from mesenchymal stem cells is reduced and the differentiation into adipocytes is increased as the aging progresses.
On the other hand, citron is a kind of citrus produced in Korea, China, Japan and Northeast Asia. The Korean is the most fragrant and the skin is thick. The main production areas in Korea are Goheung, Jeolla, Jeollanamdo, etc.
Vitamin C is the main ingredient of citron, which is 3 times more than lemon. It is good for cold and skin beauty, and contains many organic acids to prevent aging and fatigue. In addition, vitamin B, carbohydrates, proteins and other citrus fruits, more than the capillaries to protect the flavonoids that contain the blood vessels and block the airflow obstruction. In addition, drainage and excretion work out the waste that is accumulated in the body is sent out.
Regarding the efficacy of such citron, Korean Patent No. 854,403 discloses a process for producing citron extract, which comprises extracting citron seeds with ethanol and drying the citron seed extract, which is a dry powder obtained by ethanol extraction, Discloses a food exhibiting an obesity-suppressing effect comprising a composition wherein the leaf extract powder is comprised between 3: 7 and 6: 4 (w / w). Korean Patent No. 1,492,470 discloses a method for producing yuza seed oil having enhanced atherosclerotic potential and Korean Patent No. 1,383,145 discloses a composition for prevention and treatment of benign prostatic hyperplasia including citron extract. .
However, the efficacy of citrus juice for osteoporosis has not yet been elucidated.
It is an object of the present invention to provide a pharmaceutical composition and a health functional food which are excellent in osteoporosis prevention and treatment efficacy and have little side effects even when taken for a long time. In particular, we have developed a technique that can reduce differentiation from mesenchymal stem cells into adipocytes and promote osteoblast differentiation and activity.
The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis, which contains an alcohol extract of citron as an active ingredient.
The composition may be one that promotes osteoblast differentiation and activity.
The alcohol may preferably be ethanol.
The extract can be obtained by mixing 0.1 to 20 g of citron peel powder with 100 ml of alcohol and extracting at a temperature of 20 to 60 ° C for 12 to 36 hours.
The composition may be formulated in the form of powders, granules, tablets, hard capsules, soft capsules or injections.
The composition may further comprise one or more pharmaceutically acceptable carriers selected from the group consisting of diluents, excipients, disintegrants, binders and glidants.
In another aspect, the present invention relates to a health functional food for preventing or improving osteoporosis containing an alcohol extract of citron as an active ingredient.
The composition may be one that promotes osteoblast differentiation and activity.
The alcohol may preferably be ethanol.
The extract can be obtained by mixing 0.1 to 20 g of citron peel powder with 100 ml of alcohol and extracting at a temperature of 20 to 60 ° C for 12 to 36 hours.
In another aspect, the present invention provides a process for preparing a fermented beverage comprising: (a) lyophilizing the peel of citron to obtain a powder, and then mixing 0.1 to 20 g of citron powder per 100 ml of alcohol; (b) agitating the mixture at a temperature of 20 to 60 DEG C for 12 to 36 hours to elute the active ingredient; And (c) removing the solid content from the extraction solution, concentrating only the supernatant, and concentrating the extract.
The average particle size of the citron powder mixed in the alcohol in the step (a) is preferably 0.1 to 0.5 占 퐉.
The extraction temperature in step (b) is preferably 20 to 30 ° C.
The step (c) may further comprise lyophilizing the concentrated liquid to obtain a powder.
The composition may be one that promotes osteoblast differentiation and activity.
The alcohol may preferably be ethanol.
The pharmaceutical composition and the health functional food containing the citrus peel extract of the present invention as an active ingredient are useful for reducing osteoblastic differentiation from mesenchymal stem cells and promoting osteoblast differentiation and activity, It has the advantage of less side effects even when taken.
Also, the present invention relates to a method for extracting citron citron extracts, which is excellent in prevention and treatment of osteoporosis without destroying the active ingredients of osteoporosis prevention and treatment efficacy as much as possible.
Fig. 1 shows experimental results of Example 1 in which the effect of the citron extract of the present invention on osteoblast differentiation activity was evaluated.
FIG. 2 and FIG. 3 show the results of the experiment according to Example 2, which evaluated the effect of the citron extract of the present invention on bone formation of osteoporosis-induced rats.
FIG. 4 shows the results of the experiment according to Example 3 in which the citron extract of the present invention was evaluated for the influence of osteoporosis-induced rats on lipid formation.
Hereinafter, the present invention will be described in detail.
Pharmaceutical composition for preventing or treating osteoporosis
In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating osteoporosis containing an alcohol extract of citron as an active ingredient.
The alcoholic extract of citron reduces the differentiation from mesenchymal stem cells into adipocytes and promotes osteoblast differentiation and activity, and thus can be usefully used as a pharmaceutical composition for the prevention or treatment of osteoporosis.
The solvent used for the extraction of the alcoholic extract of citron may be ethanol. Specifically, 0.1 to 20 g of citrus peel powder is mixed with 100 ml of alcohol, and extraction is carried out at a temperature of 20 to 60 ° C for 12 to 36 hours . ≪ / RTI > A preferred method for producing the alcoholic extract of citrus peel used in the present invention will be described in more detail below.
As used herein, the term osteoporosis refers to a state in which the amount of bone is reduced and the strength of the bone is weakened due to a qualitative change, and the prevention, improvement and treatment of osteoporosis includes all kinds of diseases caused by decreased bone density and bone loss .
The pharmaceutical composition according to the present invention can be administered orally or parenterally at the time of clinical administration and can be used in the form of a general pharmaceutical preparation. Each can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppository sterilized injection solutions, pre-filled injection solutions or lyophilized form But is not limited thereto.
In the case of formulation, it may be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used.
Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, gelatin, . In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. may be included in addition to water and liquid paraffin which are simple diluents commonly used have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
The composition of the present invention may contain at least one active ingredient which exhibits the same or similar function in addition to the above extract.
The preferred dosage of the pharmaceutical composition of the present invention can be appropriately selected depending on the condition and the weight of the patient, the degree of symptoms, the drug form, the administration route and the period. It is preferable for the composition of the present invention to allow the active ingredient to be administered at 0.2 mg / kg to 200 mg / kg per day for optimal efficacy. The administration may be carried out once a day or divided into several doses, but is not limited thereto.
Health functional food for preventing or improving osteoporosis
In another aspect, the present invention relates to a health functional food for preventing or improving osteoporosis containing an alcohol extract of citron as an active ingredient.
The alcoholic extract of citron reduces the differentiation from mesenchymal stem cells into adipocytes and promotes osteoblast differentiation and activity, and thus can be usefully used as a health functional food for preventing or improving osteoporosis.
The solvent used for the extraction of the alcoholic extract of citron may be ethanol. Specifically, 0.1 to 20 g of citrus peel powder is mixed with 100 ml of alcohol, and extraction is carried out at a temperature of 20 to 60 ° C for 12 to 36 hours . ≪ / RTI > A preferred method for producing the alcoholic extract of citrus peel used in the present invention will be described in more detail below.
The health functional food of the present invention can be manufactured in various forms such as, but not limited to, various drinks, gum, tea, confectionery, vitamin complex, health supplement and the like.
In addition, the health functional food of the present invention includes a case where it is added to a health food for the purpose of improving osteoporosis, and there is no particular limitation on the kind of the food. Examples of the food to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.
The preferred intake amount of the health functional food of the present invention varies depending on the condition and body weight of the recipient, the degree of symptoms, the type of food, and the period of consumption, and can be appropriately selected. It is preferable for the health functional food of the present invention that the active ingredient is ingested at 0.2 mg / kg to 200 mg / kg per day for optimal effect.
Process for the production of citron extract for the prevention or treatment of osteoporosis
In another aspect, the present invention provides a process for preparing a fermented beverage comprising: (a) lyophilizing the peel of citron to obtain a powder, and then mixing 0.1 to 20 g of citron powder per 100 ml of alcohol; (b) agitating the mixture at a temperature of 20 to 60 DEG C for 12 to 36 hours to elute the active ingredient; And (c) removing the solid content from the extraction solution, concentrating only the supernatant, and concentrating the extract. The process for producing the citron extract according to the present invention will be described step by step.
First, (a) the peel of citron is lyophilized to obtain a powder, and 0.1 to 20 g of citron powder per 100 ml of alcohol are mixed.
The citron powder is obtained by lyophilization of citron peel. The average particle size of citron powder mixed with alcohol is preferably 0.1 to 0.5 mu m, more preferably 0.25 mu m or less. When citron powder having an average particle size of 0.1 to 0.5 탆 is used, there is an advantage that the effective ingredient can be effectively extracted even at a low temperature for a short time while minimizing destruction of the effective ingredient for prevention of osteoporosis. On the other hand, in order to control the particle size of the obtained citron powder by lyophilization, the powder may be pulverized by a pulverizer or the citron powder may be passed through a sieve to select only particles of a desired size.
Alcohols used as extraction solvents include, but are not limited to, lower alcohols of 1 to 4 or polyhydric alcohols, or mixtures thereof. Preferably the alcohol is ethanol. When ethanol is used as the extraction solvent, it can extract the active ingredient more effectively, reduce the complexity of the extracted compound, have low cost, low toxicity, and easy to remove.
The ratio of the extraction solvent to the citron powder is preferably 0.1 to 20 g of citron powder per 100 ml of alcohol, more preferably 5 to 15 g, particularly preferably about 10 g per citron of 100 ml of alcohol.
Next, (b) the active ingredient for osteoporosis treatment is eluted from the citron while stirring the mixture of the extraction solvent and the citron powder at a temperature of 20 to 60 DEG C for 12 to 36 hours. In this case, the extraction temperature is more preferably 20 to 30 ° C, and most preferably, it is extracted at about room temperature of about 25 ° C. If the extraction temperature is higher than the above range, the active ingredient may be destroyed. If the extraction temperature is low, the extraction time becomes longer and the economical efficiency is lowered. The extraction time may vary depending on the extraction temperature, but most preferably about 24 hours.
When the extraction is completed, (c) the solid content is removed from the extraction solution, and only the supernatant is collected and concentrated. Separation of the solids and the supernatant may be carried out, for example, using a filter paper, or by centrifugation. In addition, (d) lyophilization of the concentrate of step (c) may include the step of obtaining a powder.
Hereinafter, the process for producing the citrus juice extract of the present invention, its pharmaceutical composition and its application as a health functional food will be described in more detail with reference to the following Preparation Examples and Preparation Examples. However, the following Preparation Examples and Preparation Examples are for the purpose of specifying the content of the present invention, but the present invention is not limited by Examples.
< Manufacturing example >
Manufacturing example 1. Preparation of citron extract
Citrus peel was dried and then pulverized using a crusher. At this time, the average particle size of the citron powder is 0.1 to 0.5 占 퐉. To 100 g of the citron powder was added 500 ml of an aqueous 70 vol.% Ethanol solution. The mixture was extracted with stirring at 25 DEG C for 24 hours, and then the solid content was removed at 8,000 DEG C for 30 minutes using a centrifuge (Beckman, USA). The centrifuged supernatant was collected, concentrated under reduced pressure, and lyophilized to give a powder.
< Formulation example >
Formulation example One: Sanje Produce
Citron powder (Preparation Example 1) - 300 mg
Lactose ------------------------------ 100 mg
Talc ------------------------------ 10 mg
The above components are mixed and filled in airtight bags to prepare powders.
Formulation example 2: Preparation of tablets
Citron powder (Preparation Example 1) - 50 mg
Corn starch ------------------------------ 100 mg
Lactose ------------------------------ 100 mg
Magnesium stearate ----------------------------- 2 mg
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
Formulation example 3: Preparation of capsules
Citron powder (Preparation Example 1) - 50 mg
* Corn starch ------------------------------ 100 mg
Lactose ------------------------------ 100 mg
Magnesium stearate ----------------------------- 2 mg
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
Formulation example 4: Preparation of injection
Citron powder (Preparation Example 1) - 50 mg
Sterile sterilized distilled water for injection ---------------------------
pH adjusting agent -----------------------------
(2 ml) per 1 ampoule according to the usual injection preparation method.
Formulation example 5: Liquid Produce
Citron powder (Preparation Example 1) - 100 mg
Isomer ------------------------------ 10 g
Mannitol ------------------------------ 5 g
Purified water ------------------------------
Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.
Formulation example 6: Of health food Produce
Citron powder (Preparation Example 1) - 1000 mg
Vitamin mixture ------------------------------
Vitamin A Acetate -------------------------- 70 g
Vitamin E ------------------------------ 1.0 mg
Vitamin B1 ------------------------------ 0.13 mg
Vitamin B2 ------------------------------- 0.15 mg
Vitamin B6 ------------------------------ 0.5 mg
Vitamin B12 ------------------------------ 0.2 g
Vitamin C ------------------------------ 10 mg
Biotin ------------------------------- 10 μg
Nicotinic amide ------------------------------ 1.7 mg
Folic acid ---------------------------------- 50 μg
Calcium pantothenate ------------------------------ 0.5 mg
Inorganic mixture -------------------------------
Ferrous sulfate ------------------------------ 1.75 mg
Zinc oxide ------------------------------ 0.82 mg
Magnesium carbonate ------------------------------ 25.3 mg
Potassium phosphate monohydrate 15 mg
Secondary phosphate knife ------------------------ 55 mg
Potassium citrate -------------------------- 90 mg
Calcium carbonate -------------------------------- 100 mg
Magnesium Chloride ------------------------------- 24.8 mg
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
Formulation example 7: Manufacture of health drinks
Citron powder (Preparation Example 1) - 1000 mg
Citric acid ------------------------------ 1000 mg
oligosaccharide ---------------------------- 100 g
Plum concentrate ----------------------------- 2 g
Taurine ------------------------------ 1 g
Purified water was added to the whole to 900 ml
The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The resulting solution was filtered and sterilized in a sterilized 2 L container, ≪ / RTI > Although the composition ratio is relatively mixed with a component suitable for a favorite beverage as a preferred embodiment, the blending ratio may be arbitrarily varied depending on the regional or national preference such as the demand class, the demanding country, and the usability.
Hereinafter, the effects of the alcohol extract of citron according to the present invention on osteoporosis treatment and prevention activity will be described in more detail with reference to the following examples.
< Example >
Example 1. Measurement of effect on osteoblast differentiation activity
(1) Survival rate
To measure the effect of citron extract on the survival of osteoblasts, citron extracts of 50 μg / ml, 100 μg / ml, 200 μg / ml and 400 μg / ml were added to mouse-derived MC3T3-E1 cells And the survival rate was measured after 48 hours. As a result, the cell growth rate was increased in all the groups to which citron extract was added, and the cell growth rate was remarkably increased in the group to which 100 μg / ml or more citron extract was added (see FIG. 1A).
(2) ALP activity effect
The effect of citron extract on osteoblastic activity was investigated by measuring ALP (alkaline phosphate) activity. First, to induce osteoblast differentiation Cells were seeded in a 24-well plate at 5 × 10 4 cells per well and cultured for 2 days. Then, the cells were cultured in a differentiation induction medium (50 μg / mL L-ascorbic acid and 10 mM β-glycerophosphate). When the medium was changed every 3 days, the differentiation inducing agent and the citron extract were treated at the same concentration.
After induction of differentiation, the cells were washed twice with PBS, and lysed by adding 80 μl / well of 0.2% Triton-X-100 lysis buffer (kit product). After stirring for 10 minutes at 4 ° C, the supernatant was separated by centrifugation at 2500 × g for 10 minutes.
20 μl of supernatant was added to a 96-well plate and 20 μl of pNPP solution (kit product) was added to the supernatant. After incubation at 37 ° C for 30 min, the reaction was stopped by adding 15 μl of stop solution. The absorbance was measured at 405 nm and the amount converted to p-nitrophenol by ALP enzyme was calculated. Since ALP activity may be affected by the number of cells, the amount of total protein was measured to adjust the ALP activity.
As a result, when 50 μg / m, 100 μg / ml and 200 μg / ml of citron extract were added to MC3T3-E1 cells, the ALP activity was increased in all concentrations in a concentration-dependent manner, ml, it was confirmed that the ALP activity was superior to that of the positive control (treated with 100 nM estrogen) (see Fig. 1B) . ALP is a biomarker expressed in the differentiation of osteoblast, and it was confirmed that citron extract promotes osteoblast differentiation.
(3) Calcification Formability
Differentiation-induced cells were fixed with 4% formalin at room temperature for 10-30 minutes or overnight at 4 ° C, and then washed 2-3 times with distilled water. A solution of Alizarin Red (0.4 g / 20 mL, pH 4.6) was added to each well and stained for 5 minutes. After washing several times with distilled water, 1 mL of 10% acetylchloride dissolved in 1 mM sodium phosphate was added and shaken in a shaker for 20 minutes to dissolve the Alizarin Red staining. The absorbance was measured at 562 nm.
The results showed that Alizarin staining and absorbance were increased in proportion to the concentration of citron extract. Since calcitization ability is a biomarker important for osteoblast differentiation, Alizarin is stained in the matrix of mineralized cells, and thus the calcified amount and the degree of staining are in proportion to each other. As a result, it is confirmed that osteoblast is calcified in the extract of citron of the present invention (See Figs. 1C and 1D).
Example 2. Measure the effect on osteoporosis
In order to investigate the effect of citron extract on osteogenesis of osteoporosis-induced rats, 2-month-old female rats were divided into normal group (SHAM), ovariectomized group (OVX), female hormone (17-beta-estradiol ), Ovariectomized group (OVX + Es) injected with ovariectomized group (OVX + Es) injected with 5% / kg d 1 et / Were prepared, and the following experiment was carried out.
(One) Weight, intake and uterine weight change in osteoporosis-induced rats
The changes in body weight, the intake and the intake efficiency, the liver weight, the fat weight and the uterine weight of the four groups of rats were measured after 10 weeks, and the results are shown in Table 1.
(FER,%)
2) OVX: ovariectomized group
3) OVX + ES: ovariectomized group injected with female hormone (17-beta-estradiol)
4) OVX + citron: ovariectomized group injected with citron extract
# p < 0.05, ### p < 0.001 OVX vs.. SHAM; * p < 0.05, * * p < 0.01, *** p < 0.001, OVX + Es, OVX + OVX.
As shown in Table 1, in the group injected with citron extract (OVX + citron) according to the present invention, an increase in body weight was observed compared with that in the ovariectomized group (OVX). In addition, the weight of uterus decreased in ovariectomized group was significantly restored in the group treated with citron extract.
Therefore, it was confirmed that the citron extract according to the present invention can be effectively used for prevention or treatment of osteoporosis by reducing the body weight of osteoporosis-induced rats and restoring the smaller uterus.
(2) ALP changes in osteoporosis-induced rats
ALP and osteocalcin are used as bone formation markers. Total plasma ALP, bone specific ALP, and osteocalcin concentrations were measured for the four groups of rats. The results showed that the total blood ALP and bone specific ALP levels increased significantly in the ovariectomized group (OVX) and the ovariectomized group (ovariectomized group) OVX + Es) (Fig. 2A and Fig. 2B) .
From these experimental results, it was confirmed that citron extract can be useful for preventing or treating osteoporosis by increasing bone formation.
(3) microCT Changes in bone mineral density and bone microstructure through measurement
To investigate the effect of the citron extract according to the present invention on the recovery of bone, microcontrast of the bones was examined by using a tibia on the rats of the four groups and bone mineral density (bone mineral (BMD), bone volume / total volume (BV / TV), trabecular space (Tb.Sp) and trabecular number (Tb.N) were measured.
As a result of the experiment, it was confirmed that the microstructure of the bony bone shown in the ovariectomized group (OVX) was dense in the group injected with citron extract (OVX + citron) ( see FIG. 3A), and the lowered BMD (See FIG. 3B) . (BV / TV) (Fig. 3C) and the interval between the bone elements (Tb.Sp) was significantly higher than that of the ovariectomized group (OVX + (See Figure 3D), and the number of bone trabeculae (Tb.N) increased (see Figure 3D).
Therefore, the citron extract according to the present invention can restore osteoporosis by increasing the bone mineral density and the microstructure of the bones weakened by osteoporosis.
Example 3. Measurement of the effect on lipid formation
Total-cholesterol (TG), total-cholesterol (HDL-C), and total cholesterol were measured for the four groups of rats prepared in Example 2 to examine the effect of citron extract on the lipidogenesis of osteoporosis-induced rats. LDL-C was measured. The results showed that TG, total-C, and LDL-C values were decreased in the group injected with citron extract (OVX + citron) compared to the ovariectomized group (OVX) (see FIGS. 4A, 4B, C was increased (see Fig. 4C) . That is, it was confirmed that the citron extract according to the present invention has an effect on osteoporosis by reducing blood lipid.
Claims (16)
(b) agitating the mixture at a temperature of 20 to 60 DEG C for 12 to 36 hours to elute the active ingredient; And
(c) removing the solid content from the extraction solution, concentrating only the supernatant, and concentrating the concentrate, thereby producing an oat extract for preventing or treating osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150107475A KR101760433B1 (en) | 2015-07-29 | 2015-07-29 | Composition for preventing and treatment of osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150107475A KR101760433B1 (en) | 2015-07-29 | 2015-07-29 | Composition for preventing and treatment of osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170014332A true KR20170014332A (en) | 2017-02-08 |
| KR101760433B1 KR101760433B1 (en) | 2017-07-24 |
Family
ID=58155216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150107475A KR101760433B1 (en) | 2015-07-29 | 2015-07-29 | Composition for preventing and treatment of osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101760433B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200050811A (en) | 2018-11-02 | 2020-05-12 | (주)이뮤노텍 | Composition for protecting lung using yuja pericarp |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220037610A (en) * | 2020-09-18 | 2022-03-25 | 주식회사 하람 | A composition for bone health comprising citrus extract |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008004026A1 (en) * | 2006-07-03 | 2008-01-10 | Avestha Gengraine Technologies Pvt. Ltd. | Citrus reticulata plant extracts for treating osteoporosis and the extraction process thereof |
-
2015
- 2015-07-29 KR KR1020150107475A patent/KR101760433B1/en active IP Right Grant
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200050811A (en) | 2018-11-02 | 2020-05-12 | (주)이뮤노텍 | Composition for protecting lung using yuja pericarp |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101760433B1 (en) | 2017-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6909511B2 (en) | Composition for improving bone health containing a functional fermented product using oysters | |
| KR101252639B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Ssanghwatang and Fermentation Product Thereof with Lactic Acid Bacteria | |
| KR101997060B1 (en) | Composition for prevention or treatment of muscular disorder, or improvement of muscular functions comprising fermented deer antler | |
| EP1633379A1 (en) | Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease | |
| JP2006256968A (en) | Bone metabolism ameliorant and method for producing the same | |
| JP2006083151A (en) | Composition for preventing and ameliorating osteoporosis | |
| WO2004030683A1 (en) | Remedies | |
| JP4496127B2 (en) | Herbal extract mixture and preventive or therapeutic agent for osteoporosis | |
| KR101318296B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Essential Oil of Zanthoxylum schinifolium | |
| KR101760433B1 (en) | Composition for preventing and treatment of osteoporosis | |
| KR20160115889A (en) | Composition for prevention, improvement or treatment of osteoporosis comprising extract of Sigesbeckia spp. | |
| KR101242635B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Extract of Selaginellae Herba | |
| KR101897770B1 (en) | Pharmaceutical composition for use in preventing or treating dyslipidemia containing extract of radish sprouts as an active ingredient | |
| KR20170054115A (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating osteoporosis | |
| US11786572B2 (en) | Composition for preventing or treating osteoporosis | |
| KR20160057525A (en) | composition for the prevention and treatment ofosteoporosis containing Acyranthes bidentata Blume and ginseng extract | |
| KR101898261B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating osteoporosis | |
| KR101502465B1 (en) | A pharmaceutical composition comprising Alpinia Officinarum extracts for prevention and treatment of bone diseases or anti-vascular calcification activity | |
| KR101972657B1 (en) | Composition comprising extract of Angelica decursiva Franchet et Savatieras or compounds isolated therefrom for preventing or treating osteoporosis | |
| KR20120044450A (en) | Composition for prevention or treatment of osteoporosis comprising extract of cirsii herba | |
| JP2009269834A (en) | Bone resorption inhibitor, food and drink for bone resorption inhibition and quasi drug | |
| KR20190042872A (en) | Pharmaceutical composition for use in preventing or treating osteoporosis containing extract of crown daisy as an active ingredient | |
| KR101678960B1 (en) | Composition for preventing and treatment of osteoporosis | |
| KR102464877B1 (en) | A composition for improving, preventing and treating bone-related disease comprising Allii Fistulosi Bulbus porridge | |
| KR101665093B1 (en) | Composition for teeth-alveolar bone and functional food containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |